Related Experiment Videos
Antisense oligonucleotides for cancer therapy-an overview
Rolf A Stahel1, Uwe Zangemeister-Wittke
1Division of Medical Oncology, University Hospital, Rämistrasse 100, Zurich 8091, Switzerland. rolf.stahel@usz.ch
Lung Cancer (Amsterdam, Netherlands)
|July 18, 2003
Summary
Antisense technology offers targeted cancer therapy by blocking specific messenger RNA (mRNA) to prevent disease-causing gene translation. This approach shows promise in clinical trials for various cancers and genetic diseases.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Therapeutics
Background:
- Antisense technology utilizes sequence-specific binding of oligonucleotides to target mRNA.
- This mechanism prevents gene translation, offering a targeted therapeutic strategy.
- It is applicable to malignancies and other genetic diseases.
Purpose of the Study:
- To review the mechanism of action of antisense oligonucleotides.
- To discuss new technical developments in antisense therapy.
- To highlight novel molecular targets and summarize clinical data.
Main Methods:
- Sequence-specific hybridization via Watson-Crick base pairing.
- Targeting genes involved in apoptosis, cell growth, metastasis, and angiogenesis.
- Review of clinical trial data for approved and investigational antisense compounds.
Main Results:
- Antisense oligonucleotides selectively modulate gene expression in cancer cells.
- Several antisense compounds are in clinical trials targeting key oncogenes (e.g., Bcl-2, PKC-alpha, c-raf, Ha-ras).
- One antisense drug is approved for cytomegalovirus retinitis.
Conclusions:
- Antisense technology is a promising strategy for cancer therapy and genetic diseases.
- Functional genomics and proteomics are identifying new targets for antisense intervention.
- Clinical data indicate significant potential for antisense therapeutics.